

About Us

Lundbeck Inc., a wholly owned subsidiary of H. Lundbeck A/S (CSE: LUN) of Denmark, is committed to providing innovative specialty therapies that fulfill unmet medical needs of people with central nervous system (CNS) disorders and rare diseases for which few, if any, effective treatments are available. The company has proven success in developing and commercializing high-need therapies and recently launched three products for rare disorders. Dedicated to serving patient needs, Lundbeck offers healthcare professionals and their patients comprehensive support programs to help provide access to its medications. To learn more, please visit www.lundbeckinc.com.

Lundbeck Inc. – New Name. Same Commitment.

- Headquartered in Deerfield, Ill., founded in 2000 as Ovation Pharmaceuticals Inc. and acquired in March 2009 by H. Lundbeck A/S
- Approximately 430 employees, including a U.S.-based specialty sales force
- Seventy percent of H. Lundbeck owned by a foundation that contributes millions annually to scientific research
- Named the 2009 “North American Entrepreneurial Company of the Year” by Frost & Sullivan

Proven commercial success

- Focus on innovative specialty therapies often overlooked by other pharmaceutical companies
- Three successful specialty product introductions in less than a year including a therapy for two difficult-to-treat epilepsies, a therapy for patients with a rare inherited blood clotting disorder and a treatment for a primary symptom of a rare and debilitating neurological disorder
- 17 high-need therapies approved in the U.S., six of which are orphan-designated therapies

Promising late-stage development pipeline

- Comprehensive research and development capabilities from drug discovery through commercialization
- Thirteen CNS compounds in development or under FDA review in the U.S., five of which are in phase 3 clinical trials
- Approximately 20 percent of revenue invested in research and development each year

Putting patients first

- Comprehensive reimbursement, financial and patient support programs in place, including SHARE (Support, Help and Resources for Epilepsy) and REACH (Resources, Education and Access for patients with chorea associated with Huntington’s disease), to facilitate access to Lundbeck products
- Proven expertise in developing Risk Evaluation and Mitigation Strategies (REMS) to support availability of high-need drugs with known safety risks
- Proven track record of working with patients and advocacy groups to identify and respond to patient needs

